An interventional study of Rapamune (sirolimus) 1Mg Tablet and Unilateral resistance exercise training in Muscle Atrophy and Age-Related Sarcopenia, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to male participants aged 50 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by University of Nottingham · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Muscular Atrophy by University of Nottingham — 3 open to participants now, 5 under way, none of them phase 3. Muscular Atrophy · University of Nottingham.
Among the 11 studies in Muscular Atrophy by University of Nottingham, this one is one of 2 that started in 2021, is one of 7 with no phase, and was the 8th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →3 of the 11 studies in Muscular Atrophy by University of Nottingham are open now, in 1 country. Recruiting first, the newest first:
University of Nottingham · Sites in United Kingdom
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 50 Years to 90 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 25 across the 8 interventional studies, 18 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
2 of the studies in Muscular Atrophy by University of Nottingham that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06964438University of NottinghamPostoperative Electrical Muscle Stimulation Two | 2027-02-01 |
| NCT05414292University of NottinghamImpacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Muscular Atrophy by University of Nottingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As people age, muscle mass and function is lost and exercise training is an important way to reduce the effects of this and remain independent. However, not everyone can perform this exercise and the muscle responses to exercise are often reduced in older people. So far there has been no drug found to specifically treat or reduce this problem.
Muscle size depends on the balance of muscle protein breakdown and synthesis (building). This balance is regulated by multiple signals within the body, but a particular molecule - the mechanistic target of rapamycin (mTOR), is known to play an important role. For protein synthesis to build up the muscles, this pathway is needed to start the process when triggered by eating protein or exercise. Although this would suggest that mTOR activity is good, excessive levels of this signalling seem to have negative impacts on muscle maintenance with age.
In animal studies, blocking mTOR signalling has stopped the development of a number of age-related diseases and increased health-span. Drugs that block this pathway (e.g. Rapamune) reduce the stimulation of muscle protein synthesis, possibly through changing the immune system, but conversely have also been shown to increase muscle size and reduce markers of nerve supply loss. This means that drugs which block the mTOR pathway could, in older people, help to reduce the negative impacts of excessive mTOR signalling on muscle size and function.
The investigators aim to recruit 16 healthy male volunteers over 50 years old to investigate how the drug Rapamune (which blocks the mTOR pathway) affects aged human muscle both on its own and when combined with resistance exercise training.
Skeletal muscle is known for its role in locomotion however, muscles are also important for maintaining whole-body metabolic health. Skeletal muscles represent a vast protein store, the amino acids from which can be broken down in times of fasting, infection and disease in order to provide energy and amino acids to maintain other critical organs. With increases in the ageing population, this will inevitably increase age-related co-morbidities, and also the prevalence of frailty and increased healthcare costs.
A major facet of frailty is skeletal muscle atrophy and loss of function, and critically, these are associated with poorer clinical outcomes (e.g. surgery), so mitigating age-related muscle loss is crucial for healthy ageing. The processes of muscle loss with ageing in humans are a combination of neurodegeneration of lower motor neurons and concomitant muscle fibre atrophy. While the underlying mechanisms of age-related muscle loss are unclear, a reduced responsiveness to key environmental cues, namely nutrition and movement ("anabolic resistance"), would appear to be central. To date, no pharmaceuticals have yielded the necessary safety and efficacy effects to mitigate age-related muscle loss so exercise, particularly resistance exercise training (RET), remains the most established intervention to improve muscle mass and function in older people. Nonetheless, not all older people can perform RET, and muscle growth responses to RET are diminished in older age. As such, the search for interventions to mitigate muscle ageing and maximise responses to exercise pre-/rehabilitation in terms of muscle growth and function remain key.
The mechanistic target of rapamycin (mTOR) is often termed a "master regulator" in relation to skeletal muscle homeostasis and exists in two distinct complexes, mTORc1 and mTORc2. The most established role of mTORc1 in muscle is as a cellular sensor of nutrients and movement, where signals are conveyed to mTOR substrates, regulating the rate of mRNA translation and thus muscle protein synthesis (MPS). mTOR activity is required for the stimulation of MPS by intake of dietary proteins or free amino acids, in addition to contractile activity, and as such is commonly thought of as being positive in relation to muscle mass. Additionally, administration of rapamycin (a naturally occurring compound that inhibits mTORc1) alongside exercise or nutrient-intake has been shown to reduce the stimulation of MPS. However, confounding the notion of a positive role of mTOR on skeletal muscle, hyper-activation of mTOR has been shown in both ageing rodent and human muscle, suggesting that mTOR signalling has negative impacts in relation to muscle maintenance in ageing.
Despite the positive effects of mTOR in relation to the stimulation of MPS, in animal models data suggest that pharmacological attenuation of mTOR signalling can counteract several age-related diseases and co-morbidities, and increase overall health-span. The major negative ageing traits found to be lessened by dampening mTOR signalling (i.e. with rapamycin) are related to the immune system, organ morphology, neo-plastic disease and neurological dysfunction e.g. motor control. From these studies, the beneficial effects of rapamycin on health-span are clear, but this contrasts the positive impacts mTOR signalling have on muscle. Inhibition of mTOR would be predicted to negatively impact muscle protein turnover however, this is not the case.
Indeed, recent work has challenged the notion of mTOR suppression negatively impacting skeletal muscle metabolism in a number of experimental settings. In pre-clinical models of ageing and/or muscle dysfunction, long-term administration of rapamycin did not negatively impact skeletal muscle mass in mice treated with rapamycin across the life-course. Additionally, long-term administration of rapamycin (9-22 months), showed a mitigation of muscle mitochondrial ageing, reflected by markers of mitochondrial DNA genome stability. Perhaps the most compelling evidence of rapamycin benefiting ageing muscle is from a study where rapalog (a rapamycin analog) treatment was administered to mice where hyper-active mTOR signalling was observed in aged sarcopenic animals, as is also shown in older humans. Crucially, following Rapalog treatment animals demonstrated increases in muscle fibre area in addition to a down-regulation of cellular senescence markers and genes associated with neuromuscular denervation. These works challenge the notion that in older age with mTOR hyper-activation, mTOR-inhibition would have negative effects, and it is now accepted that ageing and age-associated diseases that arise from hyperactive mTORC1 signalling may benefit from mTOR inhibitors. As such, insight into the effects of mTORc1 inhibition are needed in humans, especially in the context of "anabolic resistance", which limits both muscle maintenance and growth potential in older adults. As an immunosuppressant, rapamycin may also present benefits for the treatment of COVID-19 which is a current highly important area of emerging research.
In this study the participant will have muscle size, function and metabolism measured over a 16 week period while either taking the drug Rapamune or a placebo. They will also complete 14 weeks of unilateral resistance exercise with visits described below.
Pre-study Assessment
Twenty-four hours before attending their main pre-study assessment, participants will be asked to consume the labelled creatine (D3-labelled; Cre) and (D3) methylhistidine (3-MH) tracers.. In order to trace these tracers into urine and plasma body pools respectively, participants will be asked to provide a urine sample before consuming these tracers (which they will bring with them the following day), and the blood sample from screening will be used for 3-MH analysis to minimise participant burden. In the 24-hours between consuming the tracer drink and attending for their pre-study assessment participants will be asked to collect all urinary output for which containers will be provided. Participants will also be asked to collect spot urine samples at \~48 amd 72-hours after consuming the tracer drink.
For their main pre-study assessment, participants will be randomly assigned to either a rapamycin inhibitor (Rapamune) or placebo (matching benign capsule containing sugar to achieve as equal weight and appearance to the treatment product as possible) group (single-blind), and will report to the laboratory for their pre-study assessment day. A suite of baseline assessments will then be performed including body composition (e.g. MRI and muscle ultrasound to determine lean mass, fat mass, muscle thickness, cross-sectional area (CSA) and muscle architecture) and measures of muscle strength and function (1-RM, MVC, power, SPPBT and iEMG). These measures will be repeated throughout the intervention period to monitor temporal changes. Throughout this visit, 6 venous blood samples (\~5 ml) will be taken for the assessment of muscle protein breakdown (MPB) via the 3-MH tracer consumed the previous day.
At the end of their pre-study assessment visit, participants will begin a two week lead-in phase of Rapamune or placebo capsules. On day 13-15 of this lead-in phase, participants will attend the laboratory for their muscle biopsies (\~150 mg each), which will be collected from the vastus lateralis (VL) of both legs (rest and exercise). This bilateral biopsy collection will allow volunteers to act as their own controls by providing both an exercise trained leg and a rested leg; to also compare the effects of Rapamune combined with contractile stimulus. Biopsy sites will be closed by sutures, which are removed (and the wound site checked) after 5-7 days. After these initial biopsies, participants will be given their bolus dose of D2O to begin assessing rates of MPS. To minimise the risk of dizziness from D2O consumption, this initial dose will be split into 6-8 smaller does provided throughout the day. Two hours after their final D2O dose, participants will be asked to provide a saliva sample..
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A \<18 or >35 kg/m2
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Will take 1mg Rapamune (sirolimus) in oral tablet form daily for 16 weeks.
Drug: Rapamune (sirolimus) 1Mg Tablet · Behavioral: Unilateral resistance exercise training
Will take a placebo tablet (lactose) daily for 16 weeks
Behavioral: Unilateral resistance exercise training
Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
Also known as: Rapamycin, Sirolimus, Rapamune
Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
Also known as: Leg extension, Strength training
Change in muscle mass from baseline
To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles.
Time frame: 0 and 16 weeks
Change in muscle mass from baseline
To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles.
Time frame: 0 and 8 weeks
Change in muscle mass from baseline
To determine the impacts of rapamycin, an mTOR inhibitor, on human muscle mass through whole body muscle mass measures by MRI and D3 creatine tracer, and ultrasound of the thigh muscles.
Time frame: 0 and 5 weeks
Change in muscle strength
To determine the impacts of rapamycin on muscle function through muscle strength measures of 1 Repetition Maximum
Time frame: 0, 5, 8 and 16 weeks
Change in muscle power
To determine the impacts of rapamycin on muscle function through muscle power measured from countermovement jump analysis.
Time frame: 0, 5, 8 and 16 weeks
Change in muscle function
To determine the impacts of rapamycin on muscle function through muscle performance measures included in the short performance physical battery test (SPPBT).
Time frame: 0, 5, 8 and 16 weeks
Change in neuromuscular function
• To determine the impacts of rapamycin on muscle function through muscle-nerve electrical signals studied with electromyography (EMG).
Time frame: 0, 5, 8 and 16 weeks
Change in Muscle Protein Synthesis
To determine the impacts of rapamycin on muscle metabolism through effects on muscle protein synthesis (via D2O tracer) from muscle biopsies.
Time frame: 2, 5, and 8 weeks
Change in Muscle Protein Breakdown
To determine the impacts of rapamycin on muscle metabolism through effects on muscle protein breakdown (via 3-MH tracer) obtained from muscle biopsies.
Time frame: 2 and 16 weeks
Immune function
Collection of peripheral blood mononuclear cells to study the immune cytokine profile using an Isoplexis system
Time frame: 0, 2, 5, 8 and 16 weeks
Plan to share: Yes — Anonymised data may be shared with collaborators including anthropometric data and samples where consent is given for this.
Supporting information: Study protocol, Analytic code
Time frame: The data will be available on conclusion of the study.
Access criteria: Listed collaborators will have access on request with data given on approval by the principal investigator
No publications or documents are linked to this record.
Started Aug 2021 (actual). Primary completion is estimated for May 2027, 68 months after the start.
Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 68 months is above that.
Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus